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Background: Astrogliosis has the potential to lead to harmful effects, namely,
neuroinflammation, and to interfere with synapse sprouting. Previous studies have
suggested that Lipocalin-2 (LCN2) acts as a key target in regulating the reaction of
astrocytes. However, the underlying molecular mechanism is not fully elucidated. In
the present study, we examined the neuroprotective and anti-inflammatory effects of
Ginkgo biloba extract (EGB), a well-known extract with potential immunoregulatory
properties in the nervous system.
Methods: Triphenyltetrazolium chloride staining, hematoxylin-eosin staining, electron
microscopy, and neurological assessments were performed in a microsphere-embolized
rat model. Human astrocytes exposed to oxygen glucose deprivation (OGD) were used
for in vitro experiments. Inflammatory cytokines, multi-labeling immunofluorescence, and
Western blotting were used to investigate the molecular mechanisms underlying the
EGB-mediated anti-inflammatory effects in vivo and in vitro.
Results: EGB markedly attenuated cerebral infarction and neuronal apoptosis, reduced
the inflammatory cytokine level, and alleviated neurological deficiencies in cerebral
ischemic rats. After surgery, EGB significantly inhibited astrocyte activation, reduced
the phosphorylation of STAT3 and JAK2 and decreased LCN2 expression. In vitro,
EGB blocked OGD-induced STAT3 activation and the generation of pro-inflammatory
cytokines in human astrocytes, and these effects were significantly enhanced by LCN2
overexpression. EGB downregulated these effects enhanced by LCN2 overexpression.
Conclusion: EGB is demonstrated to mediate neuroinflammation, which protects
against ischemic brain injury by inhibiting astrogliosis and suppresses neuroinflammation
via the LCN2-JAK2/STAT3 pathway, providing insight into a promising therapeutic
strategy for ischemic stroke.
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INTRODUCTION
Stroke is the primary reason for mortality worldwide, is
responsible for approximately 6 million deaths annually and is
considered the key reason for long-term disability (Mendis et al.,
2015). Acute cerebral ischemia is caused in the great majority
of stroke cases by the occlusion of a supplying arterial vessel
(Mozaffarian et al., 2016). Inflammation and immune responses
are considered essential for the development of strokes (Fu et al.,
2015). The immune system is closely related to crucial events
determining the fate of the ischemic brain and the survival of
stroke patients. Inflammation may ultimately lead to neuronal
cell death by inducing the entry of leukocytes (Lucas et al.,
2006), the release of inflammatory cytokines (Lambertsen et al.,
2012), and apoptosis (Pettigrew et al., 2008). Some reagents
that ameliorate ischemia-induced inflammation have a protective
effect, (Zhang et al., 1994; Furuya et al., 2001) suggesting that
inflammation may be the crucial mechanism responsible for
ischemic brain injury (Chamorro and Hallenbeck, 2006).
Astrocytes respond to attacks on the CNS through a process
called astrogliosis (Barres, 2008). Several studies have clarified
the capabilities and effects of astrogliosis. Through the release of
diverse molecules, reactive astrocytes can have several impacts
on nearby cells (Pekny and Nilsson, 2005; Sofroniew, 2009).
For example, astrocytes can produce a broad repertoire of pro-
inflammatory and anti-inflammatory cytokines to target tissue
damage following trauma, ischemia, infection, degenerative
disease, or autoimmune inflammation (Argaw et al., 2012;
Zamanian et al., 2012; Kim et al., 2014). Recently, studies
have demonstrated that LCN2 is related to a number of CNS
injury conditions, such as cerebral ischemia (Jin et al., 2014),
excitotoxic injury, stab wound (Chan et al., 2014), medial
forebrain bundle transection, and lipopolysaccharide (LPS)-
induced neuroinflammation (Suk, 2016). Reactive astrogliosis
is involved in the pathogenic mechanisms of these disease,
and LCN2 expression is induced in reactive astrocytes (Jin
et al., 2014). Therefore, astrocytes and LCN2 may be potential
molecular therapeutic targets for clinicians to treat inflammatory
CNS injuries.
The therapeutic actions of Ginkgo biloba have been well-
known in traditional Chinese medicine for over 5000 years.
In 1965, G. biloba leaf extract was first introduced and
registered for use in medical practice (DeFeudis, 2003), which
commonly used for ailments, including peripheral arterial
disease, Alzheimer’s disease, short-term memory loss, depression,
and anxiety (Kleijnen and Knipschild, 1992; Curtis-Prior et al.,
1999). Accordingly, several of these molecular mechanisms have
been analyzed in various stroke models. Several studies have
demonstrated that EGB has a wide range of therapeutic activities,
Abbreviations: CCK8, cell counting kit-8; CNS, central nervous system; CXCL,
chemokine (C-X-C motif) ligand; EGB, Ginkgo biloba extract; FBS, fetal bovine
serum; GFAP, glial fibrillary acidic protein; HE, hematoxylin-eosin; HPLC, high
performance liquid chromatography; IL-1α, interleukin-1α; IL-1β, interleukin-
1β; IL-6, interleukin -6; JAK2, Janus kinase 2; LCN2, Lipocalin-2; OGD, oxygen
glucose deprivation; POAD, peripheral occlusive arterial disease; STAT3, signal
transducer and activator of transcription 3; TNF-α, tumor necrosis factor-alpha;
TTC, triphenyltetrazolium chloride; UV, ultraviolet.
such as mitochondrial function recovery (Baliutyte et al., 2014),
antioxidation (Mohamed and Abd El-Moneim, 2017), anti-
inflammation (Li et al., 2017), and apoptosis inhibition (Wang
et al., 2015).
In the present study, we investigated the extent to which
EGB can alleviate reactive astrocytes and mediate the repair
phase in stroke. We used in vitro and in vivo cerebral
ischemia models to investigate the extent that EGB can suppress
neuroinflammation, and we investigated possible associated
mechanisms. Our results showed that EGB significantly inhibited
cerebral ischemia development by downregulating the LCN2-
activated JAK2/STAT3 signaling pathway and inhibiting astrocyte
proliferation. Therefore, our findings indicated a novel role for
EGB in the treatment of cerebral ischemia.
MATERIALS AND METHODS
Microsphere-Embolized Rat Model
We used male SD (Sprague Dawley) rats with a weight of 220–
250 g (Beijing Vital River Laboratory Animal Technology Co.,
Ltd., Beijing, China). All the procedures and ethics guidelines
were approved by the Committee for Experimental Animal Use
and Care of the Chinese Academy of Medical Sciences, China.
Efforts were made to minimize the number of animals used
and their suffering. The rats were housed at a temperature and
humidity of 23 ± 1◦C and 55 ± 5%, respectively, with a 12-h
light-dark cycle. Rats had unrestricted access to food and water.
All 50 adult SD rats were randomly allocated into five groups.
Microsphere-induced cerebral embolism was conducted with
a previously described method (Moriyama et al., 2013). After
anesthetization with 40 mg/kg chloral hydrate, the common
carotid artery and right external carotid of the rats were
temporarily occluded with vascular clamps (n = 10 per group, 5
groups). A 2-mL syringe was then inserted into the right internal
carotid. Microspheres (106–212 µm in diameter, UVPMS-BY2,
Cospheric, United States) were suspended in rat serum with
1 mg/ml, and 0.2 mL of this suspension was injected into the right
internal carotid artery. After the injection, the vascular clamps
occluding the right external and common carotid arteries were
released, and then, the puncture wound was closed with suture
strings. Blood flow to the brain by the right external and common
carotid arteries recommenced after 2–3 s. Rats in the sham group
were injected with the same volume of rat serum but without
microspheres.
Drug Administration
Ginkgo biloba extract were provided in-kind by Shineway
Pharmaceutical Group (Shijiazhuang, China), it contains total
ginkgo flavone-glycosides from G. biloba. The quantitative
analysis results showed that it contained 49% of total flavones
(UV), 28.7% of sum of glycosides with aglycone of quercetin,
isorhamnetin and kaempferol (HPLC-UV), 11.6% of sum of
gingkolide A, B, C and bilobalide with 3.3% of gingkolide
A (HPLC-UV) among them in gingko extract (Zhang et al.,
2018). The EGB preparations were manufactured in a Good
Manufacturing Practice certified facility. EGB was injected into
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the duodenum of the rats after cerebral ischemia surgery at doses
of 7.5 and 15 mg/kg. Then EGB was intragastrically administrated
at 24 h and 48 h after surgery. Rats in the sham group were
administered the same volume of saline.
Evaluation of Neurological Deficits
Scores pertaining to the neurological deficits of the rats were
calculated for each group after 2 h of ischemia and 24 h. These
scores were conducted based on a five-point scale adapted from
a previous publication (Bederson et al., 1986). Specifically, if a rat
demonstrated normal spontaneous movements (no neurological
deficit), they were assigned a score of 0; if a rat was unable to fully
extend its right paw, they were assigned a score of 1; if a rat circled
in a clockwise motion, they were assigned a score of 2; if a rat fell
to the right, they were assigned a score of 3; if a rat was unable to
walk, they were assigned a score of 4. All neurological assessments
were conducted by a researcher blinded to all groups.
Measurement of Cerebral Infarction
Forty-eight hours after cerebral ischemia, 40 mg/kg chloral
hydrate was administered to anesthetize the rats. Before
decapitation, blood serum was collected using the abdominal
aorta method. The brain was then detached, and 1-mm-thick
coronal slices were acquired and fixed in prewarmed 2 % TTC for
10 min. Finally, the slices were fixed in 10% paraformaldehyde for
30 min.
Electron Microscopy
At 48 h after cerebral ischemia, cerebral cortex slices measuring 1
cubic millimeter were crafted into square pieces with a vertex at
the center of the ischemic area comprising part of the penumbra
and undamaged area. These pieces were fixed for 2 h with 2.5%
glutaraldehyde in PBS at room temperature. The pieces were
washed with PBS, incubated for 1 h in PBS solution containing
1% OsO4, dehydrated with ethanol, contrast-stained with 1%
uranyl acetate, and embedded in EPON resin. Ultrathin sections
were prepped and observed using the ultramicrotome Leica EM
UC6 and a transmission electron microscope HITACHI H-7500
(HITACHI, Japan), respectively.
Human Astrocyte Culture and
Transfection
Astrocytes were purchased from ScienCell Research Laboratories
(CA, United States). In this study, cells were grown in Normal
astrocyte media (AM) (Sicencell, United States) containing 10%
FBS (Gibco, United States), 1% l-glutamine, and 1% penicillin-
streptomycin in a humidified atmosphere of 5% CO2 at 37◦C.
The expression vector of the LCN2 gene (EX-m0282-Lv201)
and the vector control (EX-NEG-Lv201) were obtained from
GeneCopoeia (Rockville, United States). After cells reached 70%
confluence, the astrocytes were stably transfected using 7.5 µl/ml
lentiviral vector (LPP-m0282-Lv201-100) from GeneCopoeia
(Rockville, United States) for 24 h. Then, the cells were
given normal astrocyte media (AM) (Sicencell, United States)
containing 10% FBS (Gibco, United States) without lentiviral
vector for 48 h.
Oxygen Glucose Deprivation (OGD)
Management and Treatment
After purification and transfection, human astrocytes were
cultured in an incubator with premixed gas (1% O2, 94% N2, 5%
CO2) for 6 h using deoxygenated DMEM without glucose or FBS.
After 6 h, the cells were given normal AM containing 10% FBS
and were transferred to a CO2 incubator with 95% air and 5%
CO2 environment for 12 h. The cells in the control group were
simultaneously cultured with normal AM and 10% FBS. During
OGD induction, astrocytes were treated by 2.5, 5, or 10 mg/L of
EGB for 6 h.
Western Blotting
The protein from tissues containing ischemic penumbra were
harvested at 24, 48 h after cerebral ischemia was extracted by
RIPA buffer (Beyotime Biotechnology, Shanghai, China) and was
mixed with protease and phosphatase inhibitor cocktails (MCE,
NJ, United States). The protein concentration was determined
using a protein assay solution (Bio-Rad). Identical quantities
of protein were denatured using protein loading buffer, loaded
onto 10% SDS–PAGE gels, and transferred to polyvinylidene
difluoride (PVDF) membranes by electroblotting. The PVDF
membranes were blocked by 5% bovine serum albumin (BSA)
in TBST buffer for 1 h and were incubated overnight at
4◦C using the following antibodies: LCN2 (Abcam, 1:2000
dilution), GFAP (Proteintech, 1:2000), p-JAK2 (Tyr1007/1008)
(Abcam, 1:1000), JAK2 (Abcam, 1:2000), p-STAT3 (Tyr705)
(Cell Signaling Technology, 1:2000), STAT3 (Cell Signaling
Technology, 1:2000), and β-actin (Sigma, 1:5000). Reactive bands
were detected using ECL detection reagent (Thermo Fisher
Scientific, MA, United States) following the manufacturer’s
instructions. The protocols for cell culture experiments were the
same as those described above.
Immunofluorescence Analysis and
Hematoxylin-Eosin (HE) Staining
At 48 h after cerebral ischemia, paraffin-embedded segments
were used to evaluate the expression of GFAP, LCN2, p-STAT3,
and p-JAK2 according to immunohistochemical protocols (n = 5
per group). Brain tissues were fixed in 4% paraformaldehyde
in PBS (0.01 M, pH 7.4) for 24 h at 4◦C, dehydrated in a
graded series of alcohols, and embedded in paraffin. Brain tissues
were cut into 5-µm-thick sections using a Leica R© RM1850
rotary microtome (Leica Microsystems, Germany). To eradicate
endogenous peroxidase activity, the sections were incubated
in 3% H2O2 and 3% normal goat serum. The sections were
then incubated for 1 h at 37◦C using the following rabbit
polyclonal antibodies: LCN2 (Abcam, 1:200), GFAP (Proteintech,
1:200), p-JAK2 (Tyr1007/1008) (Abcam, 1:50), JAK2 (Abcam,
1:200), p-STAT3 (Tyr705) (Cell Signaling Technology, 1:100),
and STAT3 (Cell Signaling Technology, 1:200). The sections
were rinsed with PBS and incubated with secondary antibodies
(Cell Signaling Technology, 1:100) at room temperature for
45 min; then, the sections were developed by diaminobenzidine
and counterstained with hematoxylin. Secondary antibodies,
biotinylated conjugates, and diaminobenzidine were obtained
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using a streptavidin-peroxidase kit, and the resulting signals were
imaged. Brain sections were counterstained with Hoechst 33342
(10 µg/mL) for 15 min to distinguish the nucleus. To obtain color
images, a 20 × laser scanning confocal microscope (Olympus
FV1200, Tokyo, Japan) was utilized.
Determination of Chemokine/Cytokine
Expression in Brain Extracts, Serum
Samples and Astrocytes
The chemokine and cytokine concentrations in brain hemisphere
extracts, serum samples and astrocytes conditioned in medium
were quantified by the EMD Millipore’s MILLIPLEX R© MAP Rat
Cytokine/Chemokine Magnetic Bead assay in compliance with
the manufacturer’s instructions. The chemokine and cytokine
concentrations from tissues containing ischemic penumbra were
harvested at 48 h after cerebral ischemia was extracted by EMD
Millipore’s buffer. Blood serum was collected using the abdominal
aorta method. The chemokine and cytokine concentrations in
astrocytes conditioned in medium were harvested after OGD
induction. The cytokines TNFα, IL-1α, IL-1β, and IL-6 and
the chemokine CXCL10 (IP-10) were analyzed. The median
fluorescence intensity was assayed on a FLEXMAP 3DTM system.
A five-parameter logistic method was performed to approximate
the cytokine and chemokine concentrations in both the brain
homogenates and serums samples.
Statistical Analyses
All statistical data were analyzed using GraphPad Prism software
(San Diego, CA, United States). The results are expressed as the
means ± SEM. Each experiment was performed in triplicate.
Multiple group comparisons were analyzed using one-way
analysis of variance (ANOVA). Student’s t-test was conducted to
analyze intergroup comparisons. For neurological studies, two-
way ANOVA was conducted for intergroup pairwise comparisons
as a function of time. P-values of (P < 0.05) were considered
statistically significant.
RESULTS
EGB Protected Against Cerebral
Ischemia-Induced Brain Injury
Ginkgo biloba extract was injected into the duodenum of
rats after the occurrence of cerebral ischemia. Brain infarct
volumes were determined by TTC assay 48 h after surgery. EGB
dose-dependently reduced brain infarct volume. Accordingly,
the neurological deficit scores mirrored the results of infarct
volume, indicating the protective effects of EGB. These data
suggested a neuroprotective role of EGB in reperfusion after
ischemia. Compared to the cerebral ischemia group, the EGB-
7.5 (7.5 mg/kg, daily) and EGB-15 (15 mg/kg, daily) groups
had a significant reduction in neurological deficit scores
(P < 0.05). Moreover, the neurological deficit score in the EGB-
15 group was less than that in the EGB-7.5 group. Figure 1C
shows the neurological deficit scores for all groups at 2 and
24 h after surgery and the occurrence of cerebral ischemia,
respectively.
Figures 1A,B show the infarct volume of all groups at 48 h
after cerebral ischemia occurred. In the cerebral ischemia group,
extensive lesions were observed in the striatum, hippocampus,
and cortex. Consistent with the neurological deficit scores, the
group treated with EGB (15 mg/kg, daily) had reduced infarct
volume and showed a significant therapeutic effect compared
with the cerebral ischemia group.
Hematoxylin-Eosin staining was observed to identify the
histological changes of brain neurons for all groups (Figure 1D).
Cortex sections and hippocampal regions stained with HE
presented with neuronal loss and signs of cerebral edema, and
swollen cells were observed in the ipsilateral frontal cortex.
After surgery, several apoptotic neurons were observed with
karyopyknosis, cell gaps and debris. EGB (15 mg/kg, daily)
significantly alleviated the symptoms of apoptosis in a dose-
dependent manner. Therefore, these results indicated that
15 mg/kg EGB can reduce brain injury caused by cerebral
ischemia.
Ultrastructural Changes Associated With
EGB Treatment
Electron microscopy studies were performed to generate a
detailed evaluation of astrocyte phenotypes in the peri-infarct
area following a stroke (Figure 2). The cytoplasm of the
astrocytes was occasionally observed to be completely empty,
with dispersed organelles and fibrils (Figures 2A–E). In the
model group, swollen astrocytes adhered to the damaged area,
which indicated activation, as evidenced by a significant amount
of chromatin condensation on top of the nuclear membrane
and a large nucleolus. Activated astrocytes and two-cell fusion
were also observed (Figure 2C). These astrocytes were not
observed in the control group. Finally, EGB treatment (15 mg/kg,
daily) reduced the damage to brain tissue elements in a
dose-dependent manner, and this tissue had a more viable
appearance.
Effect of EGB on Inflammatory Markers
A significant difference in cytokine levels was observed after
surgery. For example, at 48 h, pro-inflammatory IL-1α, IL-1β
and chemokine CXCL10 (IP-10) were noted in the ipsilateral
hemisphere of the model group but were not observed in
the control group. The degree of statistical significance was
calculated at p < 0.001 for IL-1α, p < 0.001 for IL-1β,
and p < 0.01 for the chemokine CXCL10. However, EGB
significantly reduced these cytokine levels compared with those
of the cerebral ischemia group (p < 0.05, EGB-15 group
vs. model group; p < 0.01, EGB-15 group vs. model group)
(Figures 3A–C). Additionally, identical results were found in
the rats’ serum. The levels of IL-1α, IL-1β and CXCL10 in
the model group were markedly higher than those of the
sham group (p < 0.05) (Figures 3D–F). Similarly, the EGB-15
group presented with reduced cytokine levels compared with
the cerebral ischemia group (p < 0.01, EGB-15 group vs. model
group).
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FIGURE 1 | EGB treatment reduced ischemic infarct volume in the cerebral ischemia model. (A,B) Cerebral infarct volume was assessed via TTC staining 48 h after
cerebral ischemia. Neurological score (C) of rats after cerebral ischemia were assessed using a five-point scale system. Data are expressed as mean ± SEM (n = 10).
∗∗∗p < 0.01 vs. sham group; ##p < 0.01 vs. the model groups. The ischemic penumbra area in the box (D) was assessed for neuronal apoptosis using HE staining.
EGB Alleviates LCN2 Up-Regulation in a
Rodent Model of Cerebral Ischemia
Immunofluorescence staining and Western blot analysis revealed
a significant increase in brain LCN2 protein levels after cerebral
ischemia. An EGB injection into the duodenum reduced
cerebral ischemia-induced LCN2 levels. To determine the cellular
localization of LCN2 protein in the hippocampus of cerebral
ischemic rats, double-immunofluorescence staining for LCN2
and GFAP was performed in brain sections after cerebral
ischemia. LCN2 protein expression was localized to within
GFAP-positive astrocytes. Consistent with the results shown in
Figure 4, the expression of LCN2 was induced, and the number
of astrocytes in the cortex was increased in rats with cerebral
ischemia compared with the sham-operated rats. However, EGB
significantly reduced GFAP levels. The effects of EGB on astrocyte
activation, LCN2, p-STAT3, and p-JAK2 expression in the
ipsilateral peri-infarct cortical area (−1.7 to −1.9 mm from the
bregma) following cerebral ischemia were captured with a laser
confocal microscope (Olympus FV1200, Japan). To determine
the potential role of EGB and LCN2 on neuroinflammation
caused by ischemic injury, astrocyte activation status was
assessed. EGB treatment (15 mg/kg) suppressed the activation
of astrocytes in the ischemic hemisphere, as suggested by
the reduced GFAP levels detected by immunofluorescence
staining and Western blotting (p < 0.05, EGB group vs. model
group). In addition, double-immunofluorescence staining also
demonstrated that astrocytic p-STAT3 and p-JAK2 levels were
markedly increased after cerebral ischemia but were diminished
by EGB treatment (Figures 4A–C). The expression of GFAP,
LCN2, p-STAT3, and p-JAK2 was determined using Western
blot (Figures 4D–H). LCN2 was observed to increase in the
cerebral ischemia group compared to the sham group (p < 0.05).
Finally, EGB markedly downregulated LCN2 expression in the
cerebral ischemia group compared to the sham group (p < 0.01).
A similar pattern of expression was noted for p-STAT3 and
p-JAK2.
EGB Attenuates OGD-Induced Injury in
Astrocytes
CCK8 assays revealed that cell viability was significantly reduced
by OGD-induced injury. EGB (50∼200 mg/L) was observed
to have a dose-dependent toxic effect on the viability (CCK8
assay) of the human astrocytes. However, treatment with EGB
(12.5∼50 mg/L) attenuate the OGD-induced decrease in cellular
activity. Finally, the pesticide effect was noted in the 2.5 mg/L
and 5 mg/L EGB groups (p < 0.05, vs. OGD group); therefore,
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FIGURE 2 | Ultrastructural characteristics of astrocytes 48 h after cerebral
ischemia. Representative transmission electron microscopy images of
astrocytes in the peri-infarct area of stroke, at 48 h after cerebral ischemia, in
three groups of animals. (A) Normal astrocyte was observed in sham group,
(B) Swollen activated perineuronal and perivascular astrocytes were seen in
model groups, which demonstrated activation as evidenced by a significant
amount of chromatin condensation atop the nuclear membrane and large
nucleolus. The astrocytes were characterized by dispersed residual organelles
and swollen mitochondria. Astrocyte fusion was often observed (C). (D,E)
Less damage was observed in the EGB treatment group. A astrocyte,
f—fibrils. Bars: A,C,D,E 2 µm; B 1 µm.
5 mg/L EGB was administered in the following in vitro tests
(Supplementary Figure S1).
To determine the role of LCN2 in the anti-inflammatory
effects of EGB, LCN2 was overexpressed in human astrocytes.
The cells were incubated under OGD settings to simulate
an ischemic model in vitro. After OGD induction, the EGB
treatment group had significantly reduced levels of the pro-
inflammatory cytokines IL-6, IL-1β, and CXCL10 compared to
the model group (p < 0.05). This effect was enhanced by LCN2
overexpression (p < 0.05, vs. control group) (Figures 5A–C).
A change in astrocyte morphology was determined by GFAP
staining (Figures 6A–C). OGD-induced astrocyte activation was
confirmed by lengthened cellular protuberances, and this effect
was enhanced by LCN2 overexpression. EGB alleviated the
activation of astrocytes after OGD induction. To investigate the
downstream anti-inflammatory targets of EGB, the expression
levels of LCN2, p-JAK2, and p-STAT3 were examined in
human astrocytes. Compared to the control group, the OGD-
stimulated model group presented with dramatically increased
levels of GFAP, LCN2, p-JAK2, and p-STAT3 (p < 0.05,
p < 0.01) (Figures 6A–H). These effects were enhanced by
LCN2 overexpression, as evidenced by immunofluorescence
staining and Western blotting (Figure 6). EGB was observed
to markedly reduce GFAP, LCN2, p-JAK2, and p-STAT3 levels
after OGD stimulation (p < 0.05, p < 0.01). Interestingly,
in human astrocytes, EGB significantly decreased the level
of LCN2 overexpression and suppressed the phosphorylation
of STAT3 and JAK2 after OGD. No differences between
the control group and the EGB-treated control group were
observed.
DISCUSSION
In this study, a novel signaling pathway involving LCN2
for the EGB-mediated dysfunction of reactive astrocyte
properties in ischemia was reported. EGB markedly reduced
FIGURE 3 | Effects of EGB treatment on the level of cytokines/chemokines in the brain after cerebral ischemia. (A–F) Analysis showing the relative levels of the
pro-inflammatory mediators IL-1α, IL-6, and CXCL 10 (IP-10), (A–C) was in brain, (D–F) was in serum. Data are expressed as mean ± SEM (n = 5). ∗p < 0.05,
∗∗p < 0.01 and ∗∗∗p < 0.001 vs. sham group; #p < 0.05 and ##p < 0.01 vs. the model groups.
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FIGURE 4 | Effects of EGB on the activation of astrocytes and the expression of LCN2, p-JAK2, p-STAT3, in cerebral ischemia rats.
(A–C) Double-immunofluorescence staining for astrocytic LCN2, p-STAT3, p-JAK2, and GFAP expression in the ischemic penumbra area after cerebral ischemia.
The cells indicated with an arrow were magnified. Scale bar = 20 µm. (D–H) Western blots and quantitative analysis of GFAP, LCN2, p-JAK2, and p-STAT3
expression are expressed as mean ± SEM (n = 4). ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 vs. sham group; #p < 0.05, ##p < 0.01 and ###p < 0.001 vs. model
groups.
stroke damage and protected the brain cortex from damage
by decreasing infarct volume in cerebral ischemic rats.
EGB ameliorated the activation of astrocytes, reduced the
phosphorylation of STAT3 and JAK2 and decreased LCN2
expression in vivo and in vitro. However, LCN2 overexpression
was observed to markedly reverse this result. Therefore,
these results suggested that EGB exerts potent therapeutic
properties in cerebral ischemia by targeting astrocytic LCN2
and suppressing neuro-inflammatory injury via the JAK2/STAT3
pathway.
Inflammation has long been known to influence the brain
after cerebral ischemia, and modulating adaptive immunity may
prevent the post-ischemic immune response from incurring
tissue damage. Inflammatory signaling is instrumental in all
stages of the ischemic cascade, from the early damaging events
triggered by arterial occlusion, to the late regenerative processes
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FIGURE 5 | EGB suppressed OGD-induced inflammation in astrocytes in vitro. (A–C) Analysis showing the relative levels of the pro-inflammatory mediators IL-1β,
IL-6, and CXCL10 (IP-10). Data are expressed as mean ± SEM (n = 5). ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 vs. control group; #p < 0.05, ##p < 0.01 and
###p < 0.001 and vs. the indicated groups.
FIGURE 6 | The effects of EGB on the activation of astrocytes and the expression of astrocytic LCN2, p-JAK2, and p-STAT3 after OGD induction in vitro.
(A–H) Double-immunofluorescence staining for GFAP, LCN2, p-JAK2, and p-STAT3 in astrocytes after OGD induction. Scale bar = 20 µm. Western blots and
quantitative analysis of GFAP, LCN2, p-JAK2, and p-STAT3 expression. Data are expressed as mean ± SEM (n = 3). ∗p < 0.05 and ∗∗p < 0.01 vs. control group;
#p < 0.05 and ##p < 0.01 vs. the indicated groups.
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underlying post-ischemic tissue repair (Iadecola and Anrather,
2011). Since 1964, the effect of EGB on several disorders
and diseases has been examined. Specifically, the investigated
effects included (but were not limited to) cerebral insufficiency,
Alzheimer’s disease, POAD, and thrombosis (Maclennan et al.,
2002). It has been reported that EGB, as a multifunctional
neuroprotective agent, can reverse the brain oxidative damage
induced by hydrogen peroxide and amyloid β-peptide, and also
can suppress activation of astrocytes and microglia (Brunetti
et al., 2006; Tulsulkar and Shah, 2013). In the present study,
EGB was observed to reduce cerebral infarction and neuronal
apoptosis in the ischemic hemisphere. Neurological disorders
were also ameliorated in cerebral ischemic rats treated with EGB.
Accordingly, this result provided the first evidence that EGB
diminishes ischemic brain injury. The inflammatory response
has both advantages and disadvantages (Fann et al., 2013), as it
originally contributes to ischemic brain injury but then assists
tissue regeneration (Chamorro and Hallenbeck, 2006).
The inflammatory response is characterized by a release
of pro-inflammatory cytokines, including TNF-α, IL-1α, IL-
6, and IL-18, and chemokines, including CCL2, CXCL10,
and CXCL12 (Ambrosini and Aloisi, 2004). This release is
mediated by neurons, astrocytes, microglia, and endothelial cells
and can cause neuronal and glial cell death during cerebral
ischemia (Allan and Rothwell, 2001). Indeed, it is reasonable
to assume that modulating the function of pro-inflammatory
cytokines and chemokines in strokes significantly affects infarct
evolution (Lambertsen et al., 2012). Here, we demonstrated that
EGB markedly reduced pro-inflammatory cytokines/chemokines
levels, including those of IL-6, IL-α and CXCL10, in tissues
surrounding the cerebral infarction. Additionally, EGB decreased
these pro-inflammatory cytokines and chemokines in the serum.
Astrogliosis has the potential to lead to harmful effects,
namely, neuroinflammation, and to interfere with synapse
sprouting (Silver and Miller, 2004; Sofroniew and Vinters,
2010). Research has shown that cytokines and inflammatory
responses can mediate astrocyte gene expression and physiology
by impacting synaptic and neuronal functions (Sofroniew, 2014).
However, the lack of effective therapeutic treatment targeting
astrogliosis is becoming an issue of concern for clinical treatment.
LCN2 is a member of the secreted lipocalin protein family. To
date, several studies have confirmed the detrimental role of LCN2
in ischemic brains (Jin et al., 2014; Suk, 2016). In addition,
several clinical trials support the experimental laboratory findings
that LCN2 is a crucial component of neuroinflammation that
mediates brain injury in cerebral ischemia and other pathological
conditions (Chan et al., 2012; Fernandez-Cadenas et al., 2013).
A recent study showed that LCN2 is a reactive astrocyte
marker and an autocrine mediator of reactive astrogliosis
(Lee et al., 2009). LCN2 amplifies neurotoxic inflammation
through the activation of microglia/astrocytes and the induction
of pro-inflammatory cytokines and chemokines like IL-6 and
CXCL10 (Hamzic et al., 2013; Xing et al., 2014). These results
suggest EGB as a new therapeutic target for suppressing innate
immune responses during stroke. As demonstrated in the present
study, marked astrocyte activation and LCN2 up-regulation
were observed throughout the ischemic cortex area after
cerebral ischemia, while EGB treatment significantly inhibited
the activation of astrocytes and markedly decreased LCN2
expression. Astrocytes were also responsive to OGD-induced
inflammation, as evidenced by LCN2 up-regulation. Therefore,
these results provide evidence for the suppression of astrocytic
LCN2 and for its contribution to the anti-inflammatory effects of
EGB after cerebral ischemia occurs.
Constitutive activation of the JAK-STAT signaling pathway
has been reported in cerebral ischemia. Recent investigations
support a role for JAK-STAT signaling in hematopoiesis
(Kisseleva et al., 2002), immune responses (Ivashkiv, 2000),
cellular homeostasis (Schindler, 2002), gliogenesis (Sauvageot
and Stiles, 2002), and reactive astrogliosis (Na et al., 2007;
Herrmann et al., 2008). Furthermore, the activation of STAT3
by phosphorylation at Tyr705 is increased after CNS insults
(Sriram et al., 2004; Yamauchi et al., 2006). STAT3 activation has
been associated with increased neuroinflammation in cerebral
ischemia (McGuckin et al., 2013), of which found that the
JAK2-STAT3 pathway was involved in the LCN2 induction
of CXCL10 secretion and possibly other phenotypic changes
associated with reactive astrogliosis (Lee et al., 2011). In
the present study, astrocytic p-STAT3 and p-JAK2 were up-
regulated after cerebral ischemia in vivo and after OGD in vitro.
However, EGB acted as an effective JAK-STAT inhibitor in
the cerebral ischemia model and in OGD-induced astrocytes
by inducing anti-inflammatory alterations. In addition, LCN2
overexpression increased both p-STAT3 and p-JAK2 expression,
but this effect was reversed by EGB treatment. These results
confirmed that the JAK2/STAT3 signaling pathway is involved
in LCN2-induced GFAP expression and plays a key role in
LCN2 activity in astrocytes (Lee et al., 2011). Therefore, LCN2-
JAK2/STAT3 signaling may mediate the neuroprotective effect of
EGB. Thus, we inferred that EGB suppressed neuroinflammation
by inhibiting the phosphorylation of STAT3 and JAK2 in
astrocytes via LCN2 suppression. However, these results do not
explain all mechanisms underlying the protective effects of EGB.
The alleviation of LCN2 expression was postulated as a key
mechanism, as some potential indirect neuroprotective effects of
EGB may still exist.
CONCLUSION
To conclude, EGB has been demonstrated to mediate
neuroinflammation, which protects against ischemic brain injury
by inhibiting astrogliosis. JAK2/STAT3-signaling regulation
of LCN2 expression may be involved in astrogliosis and
neuroinflammation. Lastly, these results imply that LCN2
could be used as a target to therapeutically modulate astrocytic
responses and as an inflammatory tool for exploring the
possibility of EGB as a therapeutic agent.
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